<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807844</url>
  </required_header>
  <id_info>
    <org_study_id>CMCS110Z2102</org_study_id>
    <secondary_id>2016-000210-29</secondary_id>
    <nct_id>NCT02807844</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability,
      pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of
      MCS110 with PDR001 in adult patients with solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Anticipated">May 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(phase 1) Number of patients with adverse events, as a measure of safety</measure>
    <time_frame>two cycles of treatment; cycle = 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(phase 2) : Overall Response rate (ORR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall Response Rate (ORR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: progression free survival (PFS)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Overall response rate per immune related Response Criteria</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 : clinical benefit rate (CBR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 : duration of response (DOR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 : disease control rate (DCR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 : Progression Free Survival (PFS)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Duration Of Response (DOR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 : Disease Control Rate (DCR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 : Clinical Benefit Rate (CBR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pancreatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative Breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS110</intervention_name>
    <arm_group_label>Pancreatic cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast cancer</arm_group_label>
    <arm_group_label>Endometrial Carcinoma</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <arm_group_label>Pancreatic cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast cancer</arm_group_label>
    <arm_group_label>Endometrial Carcinoma</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any procedures

          -  Patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with
             measurable or non-measurable disease who have progressed despite standard therapy or
             are intolerant of standard therapy, or for whom no standard therapy exists.

        Exclusion Criteria:

          -  Patient having out of range laboratory values defined as:

          -  Creatinine clearance &lt; 40 mL/min

          -  Total bilirubin &gt; 1.5 x ULN

          -  Absolute neutrophil count &lt; 1.0 x 109/L

          -  Hemoglobin (Hgb) &lt; 9 g/dL

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Active autoimmune disease

          -  Malignant disease, other than that being treated in this study.

          -  Presence of â‰¥ CTCAE Grade 2 toxicity due to prior cancer therapy.

          -  Pregnant or lactating women

        Other protocol-defined inclusion/exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Russell</last_name>
      <phone>617-643-1820</phone>
      <email>Janice_Russell@DFCI.Harvard.edu</email>
    </contact>
    <investigator>
      <last_name>F Stephen Hodi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey McQuinn</last_name>
      <phone>713-792-0007</phone>
      <email>lmcquinn@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Aung Naing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Pancreatic carcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <keyword>Immuno oncology</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>PDR001</keyword>
  <keyword>MCS110</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

